

Testosterone

*For treatment of gender dysphoria, see the Transgender Health Services section of the Physician-Related Services/Health Care Professional Services Billing Guide.

Provide the information below, please print your answers, attach supporting documentation, sign, date and return to our office as soon as possible to expedite this request.

Please FAX responses to: (800) 869-7791. Phone: (855) 322-4082, Options 0,1,2,3.

Date of Request									
Patient		Date of Birth		Molina ID					
Pharmacy Name		Pharmacy NPI	Telepl	none Number	Fax Number				
Prescriber		Prescriber NPI	Telephone Number		Fax Number				
Medication and		Dir	ections for Use	Qty/Days Supply					
 Indicate the diagnosis for your patient (check all that apply): Late-onset (age-related) hypogonadism Chronic high-dose glucocorticoid therapy HIV-associated weight loss Osteoporosis/low trauma fracture within previous 12 months. Provide T-score: Male with delayed puberty Biologic female with advancing, inoperable metastatic breast cancer Primary hypogonadism 									
Due to: ☐ Bilateral torsion ☐ Cryptorchidism☐ Klinefelter Syndrome ☐ Orchiectomy☐ Trauma or toxic damage from alcohol or heavy metals☐ Vanishing testis syndrome					☐ Chemotherapy☐ Orchitis☐ Is				
☐ Secondary hypogonadism									
Select:	Select: Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency Pituitary-hypothalamic injury from tumors, trauma or radiation								
☐ Biologic male with severely low testosterone who are symptomatic									
☐ Other. Sp	pecify:								

2.	Provide your patient's two morning tests (between 8am to 10am) at least one week apart but no more than three months apart, demonstrating low testosterone levels (not applicable for diagnosis of metastatic breast cancer):						
	Total serum testosterone level: ng/dL T	otal serum testoste	rone level:	ng/dL			
	Free testosterone level: pg/mL F	ree testosterone lev	/el:	pg/mL			
	Date taken:	Oate taken:					
3.	Provide your patient's follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels at time of diagnosis (not applicable for diagnosis of metastatic breast cancer):						
	FSH: LH:						
4.	If HIV-associated weight loss, provide the following for your patient:						
	Actual body weight:	Ideal body weight:					
	Target body weight goal:						
	Describe any changes in their weight during the la						
5.	If chronic high-dose glucocorticoid therapy, provide the following for your patient:						
	Diagnosis requiring glucocorticoid regimen:						
	Current glucocorticoid regimen: Expe	cted duration of tre	atment:				
6.	If delayed puberty, indicate the following for your patient:						
	Has patient received a diagnosis of delayed pube NOT secondary to a pathological cause?	erty that is	□Yes	□ No			
	Has patient's family history of delayed puberty be evaluated to support differential diagnosis of delayed		□Yes	□ No			
	Has patient responded to "watchful waiting" with and psychological support in the previous 6 mont		□Yes	□ No			
	Has patient completed puberty?		□Yes	□ No			
	Is patient unable to sustain a normal serum testo concentration when not receiving testosterone th		□Yes	□ No			
7.	If metastatic breast cancer, indicate the following for your patient:						
	Has patient been postmenopausal for 1 to 5 years	9.	□Yes	□ No			
	Is patient premenopausal and has demonstrated by from oophorectomy and has a hormone-responsive			□ No			
	Is this prescribed by, or in consultation with, an oncol who specializes in treatment of metastatic breas	•	□Yes	□ No			
	What first-line metastatic breast cancer treatments	s have been used?					
	What were the outcomes?						



8. Ind	icate any of the followin	g for your patient:					
	Breast cancer or known/suspected prostate cancer				□ No		
	Significant decrease in bone or muscle mass in the last 6 months				□ No		
	Uncontrolled/poorly controlled benign prostate hyperplasia				□ No		
	At higher risk of prostat		□Yes	□ No			
	Experienced a major ca	x months	□Yes	□ No			
	Uncontrolled or poorly-controlled heart failure				□ No		
	Elevated hematocrit (>50%)				□ No		
	Untreated severe obstructive sleep apnea (OSA) Severe lower urinary tract symptoms			□Yes	□ No		
				□Yes	□ No		
	Receiving treatment for osteoporosis or low trauma fracture Severe adverse events related to testosterone therapy Pregnant or may become pregnant				□ No		
					□ No		
					□ No		
Supporting documentation required: Laboratory and testing results and chart notes documenting diagnosis.							
Prescriber Signature		Prescriber Specialty	Date				

